<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pegylated interferon (peginterferon) alfa-2a: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pegylated interferon (peginterferon) alfa-2a: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pegylated interferon (peginterferon) alfa-2a: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10136" href="/d/html/10136.html" rel="external">see "Pegylated interferon (peginterferon) alfa-2a: Drug information"</a> and <a class="drug drug_patient" data-topicid="10951" href="/d/html/10951.html" rel="external">see "Pegylated interferon (peginterferon) alfa-2a: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709197"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Risk of serious disorders:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Peginterferon alfa-2a may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Monitor patients closely with periodic clinical and laboratory evaluations. Withdraw therapy in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all, cases, these disorders resolve after stopping peginterferon alfa-2a therapy.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F206899"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Pegasys;</li>
<li>Pegasys ProClick [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867864"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Pegasys</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1029834"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Interferon</span></li></ul></div>
<div class="block dop drugH1Div" id="F15043485"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9203ca82-591f-48b9-85f3-5262945663e6">Chronic hepatitis B</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic hepatitis B (CHB) (hepatitis B e antigen [HBeAg] positive):</b> Children ≥3 years and Adolescents: SubQ: 104 mcg/m<sup>2</sup> once weekly; maximum dose: 180 mcg/dose; duration of therapy: 48 weeks. <b>Note:</b> Dosing presented is mathematically equivalent to weekly dosing presented in manufacturer's labeling: 180 mcg/1.73 m<sup>2</sup> x Body Surface Area (BSA); adolescents who reach their 18th birthday during treatment should remain on the pediatric regimen.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="16cca722-a1a6-4d17-8ffa-869e415681a6">Chronic hepatitis C</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic hepatitis C (CHC):</b>
<b>Note:</b> Although FDA approved in pediatric patients ≥5 years of age, AASLD/IDSA guidelines do not recommend the use of interferon products for the treatment of hepatitis C in children 3 to 11 years (AASLD/IDSA 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years and Adolescents: SubQ: 104 mcg/m<sup>2</sup> once weekly; maximum dose: 180 mcg/dose; in combination with ribavirin (Schwarz 2011); <b>Note:</b> Dosing presented is mathematically equivalent to weekly dosing presented in manufacturer's labeling: 180 mcg/1.73 m<sup>2</sup> x BSA; adolescents who reach their 18th birthday during treatment should remain on the pediatric regimen.</p>
<p style="text-indent:-2em;margin-left:6em;">Duration of therapy (based on genotype):</p>
<p style="text-indent:-2em;margin-left:8em;">HCV genotype 1, 4, 5, 6: 48 weeks</p>
<p style="text-indent:-2em;margin-left:8em;">HCV genotype 2, 3: 24 weeks</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Pharmacokinetic simulation and modeling (including 14 pediatric and 402 adult patients [accounting for 143 pediatric and 4,020 adult pharmacokinetic observations] from multiple clinical trials) has developed a simplified weight-band dosing for BSA ranges (see the following) to provide similar exposure to the 104 mcg/m<sup>2</sup> (180 mcg/1.73 m<sup>2</sup>) weekly regimen; direct patient experience is lacking (Brennan 2016)</p>
<p style="text-indent:-2em;margin-left:6em;">BSA 0.71 to 0.74 m<sup>2</sup>: 65 mcg/dose</p>
<p style="text-indent:-2em;margin-left:6em;">BSA 0.75 to 1.08 m<sup>2</sup>: 90 mcg/dose</p>
<p style="text-indent:-2em;margin-left:6em;">BSA 1.09 to 1.51 m<sup>2</sup>: 135 mcg/dose</p>
<p style="text-indent:-2em;margin-left:6em;">BSA &gt;1.51 m<sup>2</sup>: 180 mcg/dose</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity: </b>
<b>Note:</b> Pediatric dosing adjustments shown below correspond to the following doses in manufacturer's labeling: 78 mcg/m<sup>2</sup> = 135 mcg/1.73 m<sup>2</sup>; 52 mcg/m<sup>2</sup> = 90 mcg/1.73 m<sup>2</sup>; and 26 mcg/m<sup>2</sup> = 45 mcg/1.73 m<sup>2</sup> (Schwarz 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Depression:</i> CHB, CHC: Children ≥3 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Mild depression: No dosage adjustment required; evaluate once weekly by visit/phone call. If depression remains stable, continue weekly visits. If depression improves, resume normal visit schedule. If depression worsens after 8 weeks, consider psychiatric consultation; discontinue therapy or decrease dose to 78 mcg/m<sup>2</sup> once weekly or a further dose reduction to 52 mcg/m<sup>2</sup> once weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">Moderate depression: Decrease dose to 78 mcg/m<sup>2</sup> once weekly or a further dose reduction to 52 mcg/m<sup>2</sup> once weekly. Evaluate once weekly with an office visit at least every other week. After 8 weeks, if symptoms improve and remain stable for 4 weeks, resume normal visit schedule; may continue reduced dosing or return to normal dose. If depression remains stable, consider psychiatric evaluation and continue reduced dosing. If symptoms worsen, obtain immediate psychiatric consultation and discontinue therapy permanently.</p>
<p style="text-indent:-2em;margin-left:6em;">Severe depression: Discontinue interferon treatment permanently. Obtain immediate psychiatric consultation and therapy necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hematologic toxicity</i>: <b>Note:</b> For CHC, management dependent upon weeks of therapy</p>
<p style="text-indent:-2em;margin-left:6em;">Neutropenia:</p>
<p style="text-indent:-2em;margin-left:8em;">ANC 750 to 999/mm<sup>3</sup>:</p>
<p style="text-indent:-2em;margin-left:10em;">CHB: Children ≥3 years and Adolescents: No dosage modification.</p>
<p style="text-indent:-2em;margin-left:10em;">CHC: Children ≥5 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:12em;">Week 1 to 2: Decrease dose to 78 mcg/m<sup>2</sup> once weekly</p>
<p style="text-indent:-2em;margin-left:12em;">Weeks 3 to 48: No modification</p>
<p style="text-indent:-2em;margin-left:8em;">ANC 500 to 749/mm<sup>3</sup>:</p>
<p style="text-indent:-2em;margin-left:10em;">CHB: Children ≥3 years and Adolescents: Decrease dose to 78 mcg/m<sup>2</sup> once weekly</p>
<p style="text-indent:-2em;margin-left:10em;">CHC: Children ≥5 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:12em;">Week 1 to 2: Hold dose until ANC &gt;750/mm<sup>3</sup> then resume therapy at 78 mcg/m<sup>2</sup> once weekly. Assess WBC 3 times weekly to verify ANC &gt;750/mm<sup>3</sup>.</p>
<p style="text-indent:-2em;margin-left:12em;">Weeks 3 to 48: Decrease dose to 78 mcg/m<sup>2</sup> once weekly</p>
<p style="text-indent:-2em;margin-left:8em;">ANC 250 to 499/mm<sup>3</sup>:</p>
<p style="text-indent:-2em;margin-left:10em;">CHB: Children ≥3 years and Adolescents: Hold dose until ANC ≥1,000/mm<sup>3</sup>, then resume dose at 52 mcg/m<sup>2</sup> once weekly</p>
<p style="text-indent:-2em;margin-left:10em;">CHC: Children ≥5 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:12em;">Week 1 to 2: Hold dose until ANC &gt;750/mm<sup>3</sup> then resume dose at 52 mcg/m<sup>2</sup> once weekly</p>
<p style="text-indent:-2em;margin-left:12em;">Weeks 3 to 48: Hold dose until ANC &gt;750/mm<sup>3</sup> then resume dose at 78 mcg/m<sup>2</sup> once weekly</p>
<p style="text-indent:-2em;margin-left:8em;">ANC &lt;250/mm<sup>3</sup> or febrile neutropenia: CHB, CHC: Children ≥3 years and Adolescents: Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:6em;">Thrombocytopenia:</p>
<p style="text-indent:-2em;margin-left:8em;">Platelet count 25,000 to &lt;50,000/mm<sup>3</sup>: CHB, CHC: Children ≥3 years and Adolescents: Decrease dose to 52 mcg/m<sup>2</sup> once weekly.</p>
<p style="text-indent:-2em;margin-left:8em;">Platelet count &lt;25,000: CHB, CHC: Children ≥3 years and Adolescents: Discontinue treatment.</p></div>
<div class="block dorp drugH1Div" id="F51152508"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children and Adolescents: There are no dosage adjustment provided in manufacturer's labeling; has not been studied; based on experience in adult patients, dosing adjustment suggested</p></div>
<div class="block dohp drugH1Div" id="F51152509"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatic impairment prior to initiation:</i> Contraindicated in autoimmune hepatitis, hepatic decompensation (Child-Pugh &gt;6 [class B and C]) in cirrhotic patients before treatment, and hepatic decompensation with Child-Pugh ≥6 in cirrhotic HCV patients coinfected with HIV before treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatic impairment during therapy</i>:</p>
<p style="text-indent:-2em;margin-left:4em;">Persistent or increasing ALT elevations ≥5 times ULN but &lt;10 times ULN:</p>
<p style="text-indent:-2em;margin-left:6em;">CHB: Children ≥3 years and Adolescents: Decrease dose to 78 mcg/m<sup>2</sup> once weekly; monitor ALT weekly to ensure stable or decreasing concentrations.</p>
<p style="text-indent:-2em;margin-left:6em;">CHC: Children ≥5 years and Adolescents: Decrease dose to 78 mcg/m<sup>2</sup>once weekly; monitor ALT weekly; further reduce dose if necessary until stable or ALT decreases.</p>
<p style="text-indent:-2em;margin-left:4em;">Persistent ALT values ≥10 times ULN: CHB, CHC: Children ≥3 years and Adolescents: Discontinue treatment.</p></div>
<div class="block doa drugH1Div" id="F206903"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10136" href="/d/html/10136.html" rel="external">see "Pegylated interferon (peginterferon) alfa-2a: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9203ca82-591f-48b9-85f3-5262945663e6">Chronic hepatitis B</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic hepatitis B: </b>
<b>SUBQ:</b> 180 mcg once weekly for 48 weeks.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose:</i> If within 2 days of the usual day of administration, administer dose as soon as possible then resume prior schedule; if &gt;2 days after the usual day of administration then contact health care provider.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="49e556fc-5a6b-49cb-9bbe-bc6a18f07186">Essential thrombocythemia, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Essential thrombocythemia, advanced (off-label use): </b>
<b>SUBQ:</b> 90 mcg once weekly; adjust dose based on response or tolerance (doses ranged from 45 mcg once every 2 to 4 weeks to 90 mcg once weekly); continue as long as clinically benefiting (Quintás-Cardama 2009; Quintás-Cardama 2013).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b6367ffd-86e3-4bc9-ad9a-e45bb012e46d">Polycythemia vera, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Polycythemia vera, advanced (off-label use): </b>
<b>SUBQ:</b> 90 mcg once weekly; adjust dose based on response or tolerance (doses ranged from 45 mcg once every 2 to 4 weeks to 180 mcg once weekly); continue as long as clinically benefiting (Kiladjian 2008; Quintás-Cardama 2009; Quintás-Cardama 2013).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991432"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No dosage adjustment required.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: 135 mcg once weekly; monitor for toxicity</p>
<p style="text-indent:-2em;margin-left:4em;">End-stage renal disease (ESRD) requiring hemodialysis: 135 mcg once weekly; monitor for toxicity. If severe adverse reactions or laboratory abnormalities occur, may reduce dose to 90 mcg once weekly until adverse reactions resolve; if intolerance persists after dosage adjustment, discontinue.</p></div>
<div class="block doha drugH1Div" id="F50988718"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatic impairment prior to initiation:</i> Contraindicated in autoimmune hepatitis and hepatic decompensation (Child-Pugh &gt;6 [class B and C]) in cirrhotic patients before treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatic impairment during treatment:</i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Immediately discontinue therapy if hepatic decompensation (Child-Pugh ≥6 [class B and C]) is observed.</p>
<p style="text-indent:-2em;margin-left:6em;">HBV:</p>
<p style="text-indent:-2em;margin-left:8em;">ALT &gt;5 x ULN: Consider decreasing dose to 135 mcg once weekly or temporarily discontinuing <b>and</b> monitor LFTs more frequently. If ALT continues to rise despite dose reduction or ALT increase is accompanied by increased bilirubin or hepatic decompensation, discontinue therapy immediately. Therapy may resume after ALT flare subsides.</p>
<p style="text-indent:-2em;margin-left:8em;">ALT &gt;10 x ULN: Consider discontinuing.</p></div>
<div class="block adr drugH1Div" id="F206872"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (children and adolescents: 6%; adults: 18% to 23%), pruritus (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Growth suppression (children and adolescents: decrease &gt;15 percentiles: weight [11% to 29%], height [6% to 18%])</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (children, adolescents, and adults: 15% to 17%), anorexia (16% to 17%), diarrhea (16%), nausea (children and adolescents: 9%; adults: ≤24%), vomiting (children, adolescents, and adults: ≤24%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia (severe: 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (children and adolescents: 10%; adults: 12% to 27%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (29%; neutralizing: 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (22%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (≤19%), asthenia (children and adolescents: 9%; adults: ≤56%), depression (18%), dizziness (children and adolescents: 6%; adults: 16%), fatigue (children and adolescents: 8%; adults: ≤56%), headache (children and adolescents: 21%; adults: 27% to 54%), insomnia (19%), irritability (≤19%), nervousness (≤19%), pain (11%), rigors (35%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (28%), myalgia (26% to 37%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (children and adolescents: 15%; adults: 4%), flu-like symptoms (children and adolescents: 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (children, adolescents, and adults: 37% to 54%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatitis (8%), diaphoresis (6%), eczema (1%), skin rash (children, adolescents, and adults: 5% to 10%), xeroderma (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypothyroidism (3%), weight loss (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Decreased appetite (children and adolescents: 6%), xerostomia (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncology: Anemia (severe: 2%), lymphocytopenia (severe: 3%), thrombocytopenia (severe: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum aspartate aminotransferase (children and adolescents: 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Lack of concentration (8%), memory impairment (5%), mood changes (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (4%; dyspnea on exertion: &lt;1%), epistaxis (children and adolescents: 9%), nasopharyngitis (children and adolescents: 6%), upper respiratory tract infection (children and adolescents: 8%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Gastrointestinal: Dyspepsia</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (may include combination with ribavirin):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris, cardiac arrhythmia, pulmonary embolism</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperthyroidism, increased serum triglycerides</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholangitis, colitis, gastrointestinal hemorrhage, pancreatitis, peptic ulcer</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Aplastic anemia, thrombotic thrombocytopenic purpura</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Liver steatosis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior, coma, hallucination, lethargy, neurological signs and symptoms (including homicidal ideation, suicidal ideation, suicidal tendencies), peripheral neuropathy, psychiatric disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myositis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Corneal ulcer</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any population):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, chest pain, hypertension, supraventricular cardiac arrhythmia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Exfoliative dermatitis, Stevens-Johnson syndrome, vesicobullous reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration, diabetes mellitus, hyperglycemia, hypoglycemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Tongue discoloration</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Pure red cell aplasia</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Autoimmune disease (including rheumatoid arthritis, sarcoidosis, systemic lupus erythematosus), graft rejection (kidney, liver)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Limb abscess, infection (including bacterial infection, fungal infection, viral infection)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebral ischemia, cerebrovascular hemorrhage, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Macular edema, optic neuritis, papilledema, retinal cotton-wool spot, retinal detachment, retinal hemorrhage, retinal thrombosis, retinopathy, vision loss</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Auditory impairment, hearing loss</p></div>
<div class="block coi drugH1Div" id="F206886"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity reactions (eg, urticaria, angioedema, bronchoconstriction, anaphylaxis, Stevens-Johnson syndrome) to peginterferon alfa-2a, other alfa interferons, or any component of the formulation; autoimmune hepatitis; hepatic decompensation in cirrhotic patients (Child-Pugh score &gt;6, class B and C) before treatment; hepatic decompensation with Child-Pugh score ≥6 in cirrhotic CHC coinfected with HIV before treatment; neonates and infants (due to benzyl alcohol component)</p>
<p style="text-indent:-2em;margin-left:2em;">Combination therapy with peginterferon alfa-2a and ribavirin is also contraindicated in pregnancy; men whose female partners are pregnant; patients with hemoglobinopathies (ie, thalassemia major, sickle cell disease); coadministration with didanosine</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i>: Additional contraindications (not in US labeling): Hypersensitivity to <i>E. coli-</i>derived products; history of autoimmune disease; severe psychiatric disorder or history of severe psychiatric disorder; uncontrolled thyroid disorder; breastfeeding</p></div>
<div class="block war drugH1Div" id="F206870"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Causes bone marrow suppression, including potentially severe cytopenias; alfa interferons may (rarely) cause aplastic anemia. Ribavirin may potentiate these effects. When used in combination with ribavirin, use caution with baseline neutrophil count &lt;1,500/mm<sup>3</sup>, platelet count &lt;90,000/mm<sup>3</sup> or hemoglobin &lt;10 g/dL. Discontinue therapy (at least temporarily) if ANC &lt;500/mm<sup>3</sup> or platelet count &lt;25,000/mm<sup>3</sup>. Severe neutropenia and thrombocytopenia may occur with a greater incidence in HIV coinfected patients than monoinfected patients. Obtain CBC before treatment and monitor routinely during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic effects: Serious cutaneous reactions, including vesiculobullous eruptions, Stevens-Johnson syndrome, and exfoliative dermatitis, have been reported with use, with or without ribavirin therapy; discontinue with signs or symptoms of severe skin reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal effects: Gastrointestinal hemorrhage, ulcerative and hemorrhagic/ischemic colitis (may be fatal) have been observed with interferon alfa treatment; may be severe and/or life-threatening; discontinue immediately if symptoms of colitis (eg, abdominal pain, bloody diarrhea, and/or fever) develop. Colitis generally resolves within 1 to 3 weeks of discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Hepatic decompensation and death have been associated with the use of alpha interferons including Pegasys, in cirrhotic chronic hepatitis C patients; patients coinfected with HIV and receiving antiretroviral therapy have shown an increased risk. Monitor hepatic function closely during use; discontinue immediately if decompensation occurs (Child-Pugh score &gt;6) in monoinfected patients and (Child-Pugh score ≥6, class B and C) in patients coinfected with HIV. Instruct patients to avoid alcohol; may increase hepatic effects.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Severe acute hypersensitivity reactions (eg, urticaria, angioedema, bronchoconstriction, anaphylaxis) have been reported; prompt discontinuation and management is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuropsychiatric disorders: <b>[US Boxed Warning]: May cause or exacerbate life-threatening neuropsychiatric disorders; monitor closely; discontinue treatment with worsening or persistently severe signs/symptoms of neuropsychiatric disorders. In most cases these effects were reversible following discontinuation, but not all cases.</b> Neuropsychiatric adverse effects include depression, suicidal ideation, suicide attempt, homicidal ideation, drug overdose, and relapse of drug addiction, and may occur in patients with or without a prior history of psychiatric disorder. Avoid use in severe psychiatric disorders; use with extreme caution in patients with a history of depression.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ophthalmic effects: Decreased or loss of vision and retinopathy, including macular edema, optic neuritis, papilledema, retinal hemorrhages, retinal detachment (serous), cotton wool spots, and retinal artery or vein thrombosis, may occur or be aggravated during treatment; if any ocular symptoms occur during use, a complete eye exam should be performed promptly. Prior to use, all patients should have a visual exam and patients with preexisting disorders (eg, diabetic or hypertensive retinopathy) should have exams periodically during therapy. Discontinue if new or worsening ophthalmologic disorders occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pancreatitis: Pancreatitis, including fatal cases, has been observed with alfa interferon and ribavirin therapy. Withhold treatment for suspected pancreatitis; discontinue therapy for confirmed pancreatitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary effects: May cause or aggravate dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis obliterans, interstitial pneumonitis, pulmonary hypertension, and sarcoidosis, which may result in potentially fatal respiratory failure; may recur upon rechallenge with interferons. Monitor closely. Discontinue with pulmonary infiltrates or evidence of impaired pulmonary function. Use with caution in patients with pulmonary dysfunction or a history of pulmonary disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Autoimmune disease: <b> [US Boxed Warning]: May cause or exacerbate autoimmune disorders; monitor closely; discontinue treatment in patients with worsening or persistently severe signs/symptoms of autoimmune disease. In most cases these effects were reversible following discontinuation, but not all cases.</b> Thyroiditis, thrombotic thrombocytopenic purpura, immune thrombocytopenia (formerly known as idiopathic thrombocytopenic purpura), rheumatoid arthritis, interstitial nephritis, systemic lupus erythematosus, myositis, hepatitis, and psoriasis have been reported with interferon therapy; use with caution in patients with autoimmune disorders.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with prior cardiovascular disease; hypertension, supraventricular arrhythmias, chest pain, and MI have been observed with treatment. Patients with a history of significant or unstable cardiac disease should not receive combination treatment with ribavirin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus; hyper/hypoglycemia have been reported; may require adjustments in antidiabetic medications; discontinue if unable to effectively manage diabetes with medication.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatitis B: In hepatitis B patients, flares (transient and potentially severe increases in serum ALT) may occur during or after treatment; more frequent monitoring of LFTs and a dose reduction are recommended. Discontinue immediately if ALT elevation continues despite dose reduction or if increased bilirubin or hepatic decompensation occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infectious disorders: <b> [US Boxed Warning]: May cause or aggravate infectious disorders; monitor closely; discontinue treatment in patients with worsening or persistently severe signs/symptoms of infectious disorders. In most cases these effects were reversible following discontinuation, but not all cases.</b> Serious and severe infections (bacterial, viral, and fungal), some fatal, have been reported with treatment. Interferon therapy is commonly associated with flu-like symptoms, including fever; rule out other causes/infection with persistent or high fever.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ischemic disorders: <b>[US Boxed Warning]: May cause or aggravate ischemic disorders and hemorrhagic cerebrovascular events; monitor closely; discontinue treatment in patients with worsening or persistent ischemia. In most cases these effects were reversible following discontinuation, but not all cases</b>. Has been reported in patients without risk factors for stroke.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal dysfunction (CrCl &lt;30 mL/minute); dosage adjustment recommended; monitor for signs/symptoms of toxicity (dosage adjustment required if toxicity occurs).</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Clinical practice chronic hepatitis B treatment guidelines do not recommend use in patients with uncontrolled seizures (AASLD [Terrault 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disorders: Use with caution in patients with preexisting thyroid disease; thyroid disorders (hyper- or hypothyroidism) or exacerbations have been reported; discontinue if unable to effectively manage with medication.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly; certain adverse effects (eg, neuropsychiatric, cardiac, flu-like reactions) may be more severe.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Growth velocity (height and weight) was decreased in children with or without combination treatment with ribavirin, during the length of treatment. In clinical studies, decreases were noted in weight and height for age z-scores and normative growth curve percentiles. Following treatment, rebound growth and weight gain occurred in most patients; however, a small percentage did not. For most children with hepatitis C, posttreatment recovery in growth at 2 years posttreatment was maintained to 6 years posttreatment. In children with hepatitis B at 5 years posttreatment, the percentage of children with a decrease of more than 15 percentiles from baseline was 29% for weight and 18% for height. Growth should be closely monitored in children during therapy and posttreatment until growth catch-up has occurred.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Product variability: <b>Due to differences in dosage, patients should not change brands of interferon without the concurrence of their health care provider.</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: <i>Hepatitis B:</i> Hepatitis B genotypes A and B are more likely to achieve HBeAg and HBsAg loss with peg-interferon than non-A/B genotypes. For patients with hepatitis B coinfected with hepatitis delta virus, pegylated interferon is the only effective therapy (AASLD [Terrault 2016]).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878582"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Inhibition of growth velocity in pediatric patients may occur; in clinical trials, growth suppression of ≥15 percentiles on the normal growth curve was reported for weight in 43% of pediatric patients and for height in 25% of patients after 48 weeks of therapy. At the two-year follow-up after treatment, most children had returned to their baseline growth curve percentile; monitor growth at baseline and during therapy.</p></div>
<div class="block foc drugH1Div" id="F206881"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pegasys: 180 mcg/mL (1 mL) [contains benzyl alcohol, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pegasys ProClick: 180 mcg/0.5 mL (0.5 mL [DSC]) [contains benzyl alcohol, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pegasys: 180 mcg/0.5 mL (0.5 mL) [contains benzyl alcohol, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pegasys: 180 mcg/0.5 mL (0.5 mL [DSC]) [contains benzyl alcohol, polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F206867"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F206888"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Pegasys Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mcg/mL (per mL): $1,336.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Pegasys Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mcg/0.5 mL (per 0.5 mL): $1,336.11</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867865"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pegasys: 180 mcg/0.5 mL (0.5 mL) [contains benzyl alcohol, polysorbate 80]</p></div>
<div class="block admp drugH1Div" id="F52613543"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">SubQ: Do not shake vial, prefilled syringe, or autoinjector. For pediatric doses, the 180 mcg/mL vial should be used and doses withdrawn using a 1 mL tuberculin syringe. Allow syringe, autoinjector, or vial to reach room temperature before use. The vial may be warmed by gently rolling in the palms of the hand for ~1 minute. Allow the autoinjector to come to room temperature on its own for ~20 minutes; do not warm autoinjector any other way. Lay the prefilled syringe on a flat clean service and wait ~3 minutes, allowing it to reach room temperature; if condensation water remains on the outside of the syringe, let syringe set until it disappears.</p>
<p style="text-indent:0em;margin-top:2em;">Administer SubQ in the abdomen or thigh. Rotate injection site. Discard unused solution. Administration should be done on the same day and at approximately the same time each week.</p></div>
<div class="block adm drugH1Div" id="F206883"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">SubQ: Administer in the abdomen or thigh. Rotate injection site. Administration should be done on the same day and at approximately the same time each week.</p></div>
<div class="block sts drugH1Div" id="F206895"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store in refrigerator at 2°C to 8°C (36°F to 46°F). Do not leave out of the refrigerator for more than 24 hours. Do not freeze or shake. Protect from light. Discard any unused portion. The following stability information has also been reported:</p>
<p style="text-indent:-2em;margin-left:4em;">Intact vial: May be stored at room temperature for up to 14 days (Cohen, 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">Prefilled syringe: May be stored at room temperature for up to 6 days (Cohen, 2007).</p></div>
<div class="block meg drugH1Div" id="F7874941"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:0em;margin-left:2em;">Pegasys: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F103964s5276lbl.pdf%23page%3D37&amp;token=dWMrTIAnBt5gepQ4MwnNNwhJdZxTVxusEp4tOh%2BQzX1RzCjJZvIEymvcosoie0Xd%2BspBzME6p2bi%2BTwOuLGih48GZF6z5opoKimARk9o87J7%2BUn1UGT7Uho36FFgavlu&amp;TOPIC_ID=87809" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/103964s5276lbl.pdf#page=37</a></p></div>
<div class="block usep drugH1Div" id="F53568255"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) infection in non-cirrhotic patients with evidence of viral replication and elevations in serum ALT (FDA approved in pediatric patients ≥3 years of age); treatment of HBeAg-positive and HBeAg-negative CHB infection who have compensated liver disease and evidence of viral replication and liver inflammation (FDA approved in adults)</p>
<p style="text-indent:-2em;margin-left:2em;">Treatment of chronic hepatitis C (CHC) infection in patients with compensated liver disease in combination with ribavirin (FDA approved in pediatric patients ≥5 years); treatment of CHC infection in patients with compensated liver disease in combination with other hepatitis C virus (HCV) antiviral medications, or monotherapy if there are contraindications or significant intolerance to other HCV antiviral medications (FDA approved in adults).<b> Note:</b> Although FDA approved in pediatric patients ≥5 years of age, AASLD/IDSA guidelines do not recommend the use of interferon products for the treatment of hepatitis C in children 3 to 11 years (AASLD/IDSA 2018). In adults, peginterferon and ribavirin, typically in combination with a direct-acting antiviral, remain in use for certain genotypes, particularly in resource-limited settings where newer interferon-free regimens are not accessible (AASLD/IDSA 2017). Peginterferon alfa-2a alone or in combination with ribavirin without additional HCV antiviral drugs is not recommended for treatment of patients with chronic HCV who previously failed therapy with an interferon alfa. Peginterferon alfa-2a is not recommended for treatment of patients with CHC who have had solid organ transplantation.</p></div>
<div class="block cyt drugH1Div" id="F206913"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Inhibits</b> CYP1A2 (weak)</p></div>
<div class="block dri drugH1Div" id="F206874"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aldesleukin: Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination.  Management: Consider using lower doses to minimize toxicity of this combination. Only coadminister aldesleukin and interferons (alfa) in patients in whom potential benefits outweigh the risk of severe toxicity. Monitor renal and cardiac function closely if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fezolinetant: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Fezolinetant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: Interferons (Alfa) may increase the serum concentration of Fluorouracil Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: Interferons (Alfa) may increase the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegloticase: May diminish the therapeutic effect of PEGylated Drug Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvaliase: PEGylated Drug Products may enhance the adverse/toxic effect of Pegvaliase. Specifically, the risk of anaphylaxis or hypersensitivity reactions may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribavirin (Oral Inhalation): Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin (Oral Inhalation). Hemolytic anemia has been observed. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribavirin (Systemic): Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin (Systemic). Hemolytic anemia has been observed. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Telbivudine: Peginterferon Alfa-2a may enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible. If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Interferons (Alfa) may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zidovudine: Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F52597882"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status prior to administration in patients who could become pregnant. Disruption of the normal menstrual cycle was observed in animal studies. Patients who could become pregnant should use effective contraception during treatment.</p>
<p style="text-indent:0em;margin-top:2em;">If used in combination with ribavirin, all warnings related to the use of ribavirin and contraception should be followed. Refer to the ribavirin monograph for additional information.</p></div>
<div class="block pri drugH1Div" id="F206889"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Alfa interferon is endogenous to normal amniotic fluid (Lebon 1982); however, placenta perfusion studies note exogenous interferon alfa does not cross the placenta (Waysbort 1993). The US Department of Health and Human Services perinatal HIV guidelines recommend against the use of peginterferon-alfa during pregnancy because of its antigrowth and antiproliferative effects (HHS [perinatal] 2023). Animal reproduction studies have demonstrated abortifacient effects.</p>
<p style="text-indent:0em;margin-top:2em;">Peginterferon alfa-2a in combination with ribavirin is contraindicated in pregnant patients or patients whose partners are pregnant. Combination therapy with ribavirin may cause birth defects and death in an unborn child. All warnings related to the use of ribavirin and pregnancy should be followed. Refer to the ribavirin monograph for additional information.</p></div>
<div class="block mopp drugH1Div" id="F53568256"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Prior to treatment, pregnancy screening should occur for women of childbearing age who are receiving treatment or who have male partners who are receiving treatment. In combination therapy with ribavirin, pregnancy tests should continue monthly up to 6 months after discontinuation of therapy. Evaluate for depression and other psychiatric symptoms before and during therapy; baseline eye examination and periodically; baseline echocardiogram in patients with cardiac disease.</p>
<p style="text-indent:-2em;margin-left:2em;">In addition to disease monitoring parameters, the following were used during chronic hepatitis C clinical trials:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years and Adolescents: Hematologic and biochemical assessments were made at weeks 1, 3, 5, and 8, and then every 4 weeks thereafter; TSH measured every 12 weeks; growth parameters (height, weight, percentiles on growth curve) (Schwarz 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: CBC (including hemoglobin, WBC, and platelets) and chemistries (including liver function tests and uric acid) measured at weeks 1, 2, 4, 6, and 8, and then every 4 to 6 weeks (more frequently if abnormal); TSH measured every 12 weeks</p>
<p style="text-indent:-2em;margin-left:2em;">Additionally, the following baseline values were used as entrance criteria in adults:</p>
<p style="text-indent:-2em;margin-left:4em;">Platelet count ≥90,000/mm<sup>3</sup> (as low as 75,000/mm<sup>3</sup> in patients with cirrhosis or 70,000/mm<sup>3</sup> in patients with HCV coinfected with HIV)</p>
<p style="text-indent:-2em;margin-left:4em;">ANC ≥1500/mm<sup>3</sup></p>
<p style="text-indent:-2em;margin-left:4em;">Serum creatinine &lt;1.5 times ULN</p>
<p style="text-indent:-2em;margin-left:4em;">TSH and T<sub>4</sub> within normal limits or adequately controlled</p>
<p style="text-indent:-2em;margin-left:4em;">CD4<sup>+</sup> cell count ≥200 cells/mm<sup>3</sup> or CD4<sup>+</sup> cell count ≥100 cells/mm<sup>3</sup>, but &lt;200 cells/mm<sup>3</sup> and HIV-1 RNA &lt;5000 copies/mL in HCV patients coinfected with HIV</p>
<p style="text-indent:-2em;margin-left:4em;">Hemoglobin ≥12 g/dL for women and ≥13 g/dL for men in HCV monoinfected patients</p>
<p style="text-indent:-2em;margin-left:4em;">Hemoglobin ≥11 g/dL for women and ≥12 g/dL for men in HCV patients coinfected with HIV</p>
<p style="text-indent:-2em;margin-left:2em;">Also in adults, serum HCV RNA levels (pretreatment, 12 and 24 weeks after therapy initiation, 24 weeks after completion of therapy). <b>Note:</b> Discontinuation of therapy may be considered after 12 weeks in patients with HCV (genotype 1) who fail to achieve an early virologic response (defined as ≥2-log decrease in HCV RNA compared to pretreatment) or after 24 weeks with detectable HCV RNA (Ghany 2009).</p></div>
<div class="block pha drugH1Div" id="F206869"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Alpha interferons are a family of proteins, produced by nucleated cells that have antiviral, antiproliferative, and immune-regulating activity. There are 16 known subtypes of alpha interferons. Interferons interact with cells through high affinity cell surface receptors. Following activation, multiple effects can be detected including induction of gene transcription. Interferons inhibit cellular growth, alter the state of cellular differentiation, interfere with oncogene expression, alter cell surface antigen expression, increase phagocytic activity of macrophages, and augment cytotoxicity of lymphocytes for target cells. </p></div>
<div class="block phk drugH1Div" id="F206885"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Terminal: 50-160 hours; increased with renal dysfunction </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: 72 to 96 hours</p></div>
<div class="block phksp drugH1Div" id="F51192065"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance is decreased 43% in patients with severe renal impairment (CrCl &lt;30 mL/minute).</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Clearance was nearly 4-fold lower in children 2 to 8 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: AUC is increased in patients &gt;62 years of age.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F206891"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Optipeg A</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Pegasys | Pegferon | Reiferon retard</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Reiferon retard</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Pegasys | Pegasys pfs</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Pegasys | Pegasys 135 microgram</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Peg inf | Pegasys | Ropegra | Unipeg</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Pegasys | Pegasys ProClick</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Pegasys | Pegferon</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Pegasys</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  American Association for the Study of Liver Diseases/Infectious Diseases Society of America (AASLD/IDSA). Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Updated October 5, 2021. Accessed May 18, 2022.</div>
</li>
<li>
<div class="reference">
                  American Association for the Study of Liver Diseases/Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. HCV in children. https://www.hcvguidelines.org/unique-populations/children. Updated May 24, 2018. Accessed October 30, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29515238">
<a name="29515238"></a>Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. <i>Leukemia</i>. 2018;32(5):1057-1069. doi:10.1038/s41375-018-0077-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/29515238/pubmed" id="29515238" target="_blank">29515238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26529640">
<a name="26529640"></a>Brennan BJ, Lemenuel-Diot A, Snoeck E, et al. Use of an integrated modelling and simulation approach to develop a simplified peginterferon alfa-2a dosing regimen for children with hepatitis C. <i>Br J Clin Pharmacol</i>. 2016;81(4):658-666.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/26529640/pubmed" id="26529640" target="_blank">26529640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21160459">
<a name="21160459"></a>Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. <i>MMWR Recomm Rep</i>. 2010;59(RR-12):1-110.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/21160459/pubmed" id="21160459" target="_blank">21160459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17687059">
<a name="17687059"></a>Cohen V, Jellinek SP, Teperikidis L, et al. Room-Temperature Storage of Medications Labeled for Refrigeration. <i>Am J Health-Syst Pharm.</i> 2007;64(16):1711-1715.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/17687059/pubmed" id="17687059" target="_blank">17687059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16401485">
<a name="16401485"></a>Dienstag JL, McHutchison JG. American Gastroenterological Association Medical Position Statement on the Management of Hepatitis C. <i>Gastroenterology.</i> 2006;130(1):225-230.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/16401485/pubmed" id="16401485" target="_blank">16401485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12324553">
<a name="12324553"></a>Fried MW, Shillman ML, Reddy KR, et al. Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection. <i>N Engl J Med.</i> 2002;347:975-982.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/12324553/pubmed" id="12324553" target="_blank">12324553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19330875">
<a name="19330875"></a>Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, Management and Treatment of Hepatitis C: An Update. <i>Hepatology.</i> 2009;49(4):1335-1374.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/19330875/pubmed" id="19330875" target="_blank">19330875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22419578">
<a name="22419578"></a>Gowin K, Thapaliya P, Samuelson J, et al. Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. <i>Haematologica</i>. 2012;97(10):1570-1573. doi:10.3324/haematol.2011.061390<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/22419578/pubmed" id="22419578" target="_blank">22419578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28782502">
<a name="28782502"></a>Hughes BL, Page CM, Kuller JA; Society for Maternal-Fetal Medicine (SMFM). Hepatitis C in pregnancy: screening, treatment, and management. <i>Am J Obstet Gynecol</i>. 2017;217(5):B2-B12. doi:10.1016/j.ajog.2017.07.039.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/28782502/pubmed" id="28782502" target="_blank">28782502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatiti</i>s. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22383118">
<a name="22383118"></a>Jonas MM, Balistreri W, Gonzalez-Peralta RP, et al. Peginterferon for Chronic Hepatitis C in Children Affects Growth and Body Composition: Results From the Pediatric Study of Hepatitis C (PEDS-C) Trial. <i>Hepatology.</i> 2012;56(2):523-531.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/22383118/pubmed" id="22383118" target="_blank">22383118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18650451">
<a name="18650451"></a>Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. <i>Blood</i>. 2008;112(8):3065-3072. doi:10.1182/blood-2008-03-143537<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/18650451/pubmed" id="18650451" target="_blank">18650451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11153157">
<a name="11153157"></a>Kumar AR, Hale TW, Mock RE. Transfer of interferon alfa into human breast milk. <i>J Hum Lact</i>. 2000;16(3):226-228.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/11153157/pubmed" id="11153157" target="_blank">11153157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6176680">
<a name="6176680"></a>Lebon P, Girard S, Thepot F, et al. The Presence of Alpha-Interferon in Human Amniotic Fluid. <i>J Gen Virol.</i> 1982;59(pt 2):393-396.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/6176680/pubmed" id="6176680" target="_blank">6176680</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15371578">
<a name="15371578"></a>Marcellin P, Lau GK, Bonino F, et al. Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients With HBeAg-Negative Chronic Hepatitis B. <i>N Engl J Med.</i> 2004;351(12):1206-1217.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/15371578/pubmed" id="15371578" target="_blank">15371578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30478826">
<a name="30478826"></a>McMullin MF, Harrison CN, Ali S, et al; BSH Committee. A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology guideline. <i>Br J Haematol</i>. 2019;184(2):176-191. doi:10.1111/bjh.15648<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/30478826/pubmed" id="30478826" target="_blank">30478826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18042575">
<a name="18042575"></a>Murray KF, Rodrigue JR, Gonzalez-Peralta RP, et al. Design of the PEDS-C Trial: Pegylated Interferon +/- Ribavirin for Children With Chronic Hepatitis C Viral Infection. <i>Clin Trials.</i> 2007;4(6):661-673.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/18042575/pubmed" id="18042575" target="_blank">18042575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pegasys.1">
<a name="Pegasys.1"></a>Pegasys (peginterferon alfa-2a) [prescribing information]. Lee's Summit, MO: Summit SD LLC; December 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pegasys.2">
<a name="Pegasys.2"></a>Pegasys (peginterferon alfa-2a) [product monograph]. Mississauga, Ontario, Canada: zr Pharma&amp; GmbH; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23782935">
<a name="23782935"></a>Quintás-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. <i>Blood</i>. 2013;122(6):893-901. doi:10.1182/blood-2012-07-442012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/23782935/pubmed" id="23782935" target="_blank">23782935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19826111">
<a name="19826111"></a>Quintás-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. <i>J Clin Oncol</i>. 2009;27(32):5418-5424. doi:10.1200/JCO.2009.23.6075<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/19826111/pubmed" id="19826111" target="_blank">19826111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21036173">
<a name="21036173"></a>Schwarz KB, Gonzalez-Peralta RP, Murray KF, et al. The Combination of Ribavirin and Peginterferon is Superior to Peginterferon and Placebo for Children and Adolescents With Chronic Hepatitis C. <i>Gastroenterology. </i>2011;140(2):450-458.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/21036173/pubmed" id="21036173" target="_blank">21036173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26566064">
<a name="26566064"></a>Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH; American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. <i>Hepatology</i>. 2016;63(1):261-283. doi: 10.1002/hep.28156.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/26566064/pubmed" id="26566064" target="_blank">26566064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15282351">
<a name="15282351"></a>Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected Patients. <i>N Engl J Med.</i> 2004;351(5):438-450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/15282351/pubmed" id="15282351" target="_blank">15282351</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Accessed May 4, 2020.</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-oi/tables-pediatric-oi.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-oi/tables-pediatric-oi.pdf</a>.</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services (HHS) Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. <a href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new</a>. Updated January 31, 2023, Accessed February 23, 2023</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26242182">
<a name="26242182"></a>Vannucchi AM, Barbui T, Cervantes F, et al; ESMO Guidelines Committee. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2015;26(suppl 5):v85-v99. doi:10.1093/annonc/mdv203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/26242182/pubmed" id="26242182" target="_blank">26242182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8328774">
<a name="8328774"></a>Waysbort A, Giroux M, Mansat V, et al. Experimental Study of Transplacental Passage of Alpha Interferon by Two Assay Techniques. <i>Antimicrob Agents Chemother.</i> 1993;37(6):1232-1237.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/8328774/pubmed" id="8328774" target="_blank">8328774</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). Guidelines for the care and treatment of persons diagnosed with chronic hepatitis c virus infection. https://apps.who.int/iris/bitstream/handle/10665/273174/9789241550345-eng.pdf?ua=1. Published July 2018. Accessed April 29, 2019.</div>
</li></ol></div><div id="topicVersionRevision">Topic 87809 Version 200.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
